HTG Molecular Diagnostics Inc (NASDAQ:HTGM) a provider of instruments, services and reagents for molecular profiling applications reported that its latest direct-target sequencing chemistry will be offered in the firm’s VERI/O lab as a service offering starting 1Q2017. The new chemistry is intended for direct sequencing of detailed DNA and, in the coming period, RNA aims with the same high specificity and sensitivity as the firm’s existing HTG EdgeSeq chemistry uses.
The preliminary panel intended for the VERI/O lab will list common mutations in the KRAS, BRAF genes and for retrospective research trials mainly from difficult and small samples, like FFPE tissue.
TJ Johnson, the Chief Executive Officer of HTG Molecular, reported that they are extremely thrilled to be able to provide their clients this added service which along with their initial service offerings, provide them to offer data on major DNA mutations and comprehensive gene expression RNA outlining, all from a distinct section of FFPE tissue. They have closed their patent application submissions and intend to leverage this chemistry into numerous offerings, counting DNA applications like extended DNA mutation panels, and noticing microsatellite variability and tumor mutational burden.
Byron Lawson, the VP of Commercial Operations, reported that they are closing final preparations for releasing the direct-target sequencing know-how and a preliminary DNA mutation panel in VERI/O lab, and intend to have this panel accessible to service clients for research applications by the close of this quarter.
Headquartered in Tucson, HTG’s objective is to empower precision drug at the local level. In 2013, the firm commercialized its initial instrument platform and RNA assays portfolio that leveraged original nuclease protection chemistry.
Uninterrupted innovation quickly led to HTG’s initial sequencing-based chemistry and then in 2014, the firm released its HTG EdgeSeq product line, which mechanizes targeted and sample library preparation for next-gen sequencing.